Revision history of "DEVELOPMENT OF NEW SECOND GENERATION MOLECULES FOR CANCER IMMUNOTHERAPY" (Q4191440)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

11 October 2024

  • curprev 15:5115:51, 11 October 2024DG Regio talk contribs 67,424 bytes +8 Changed label, description and/or aliases in pt
  • curprev 15:5115:51, 11 October 2024DG Regio talk contribs 67,416 bytes −6 Set a claim value: summary (P836): A LIMMUNOTERAPIA BASEADA EM INIBITORES DE CONTROLO IMUNOLÓGICO REPRESENTA O SECTOR EMERGENTE DA TERAPIA DE CANCRO, COM UM MERCADO DE CRESCIMENTO EXPONENTIAL. Nomeadamente, os anticorpos monoclonais (MABS) capazes de inibir o CTLA-4, o PD-1 e o PD-L1, homologados para vários tumes sólidos e o linfoma de HoDGKIN, são capazes de reagir a uma resposta anticancerígena imunológica generalizada, prevendo pela primeira vez um aARMA terapêutico para paciente...

23 March 2024

14 June 2023

11 June 2023

26 April 2023

8 April 2023

7 September 2022

21 July 2022

  • curprev 21:0921:09, 21 July 2022DG Regio talk contribs 63,095 bytes +38,297 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, it, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et,

6 February 2022

4 February 2022

3 February 2022

2 February 2022

31 January 2022